Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Subacute Cutaneous Lupus Erythematosus: early-phase trial registry
2 of 2 indexed Subacute Cutaneous Lupus Erythematosus trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Subacute Cutaneous Lupus Erythematosus: 2 US clinical trials tracked, 2 recruiting.
Subacute Cutaneous Lupus Erythematosus is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Immunovant Sciences, running 1 of these trials.
Enrollment posture brief
Registry condition subacute-cutaneous-lupus-erythematosus
OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Subacute Cutaneous Lupus Erythematosus lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Subacute Cutaneous Lupus Erythematosus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Subacute Cutaneous Lupus Erythematosus is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Biogen
NCT05531565
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
Immunovant Sciences
NCT06980805
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Subacute Cutaneous Lupus Erythematosus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Subacute Cutaneous Lupus Erythematosus trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Subacute Cutaneous Lupus Erythematosus page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Subacute Cutaneous Lupus Erythematosus trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Immunovant Sciences sponsors the most Subacute Cutaneous Lupus Erythematosus trials on record, review their full trial history before evaluating a specific study. See Immunovant Sciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Subacute Cutaneous Lupus Erythematosus condition card totals 2 registered trials; most-linked intervention Placebo; top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.